ArticleWorld journal of gastrointestinal surgery2021
Immunotherapy after liver transplantation: Where are we now?
Article in World journal of gastrointestinal surgery, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 35 citations in OpenAlex.
- Immune checkpoint inhibitors in malignancies after liver transplantation: A systematic review and pooled analysis.Liver international : official journal of the International Association for the Study of the Liver · 2023Pooled it
- Asia-Pacific Transplant Oncology Symposium 2024: Expert Statements on the Current State and Future Direction of Hepatobiliary Surgical and Transplant Oncology.Liver cancer · 2026Review
- Review
- Review Article: Liver Transplantation for Hepatocellular Carcinoma in the Era of Immune Checkpoint Inhibitors.Alimentary pharmacology & therapeutics · 2025Review
- Immune Checkpoint Inhibitors and Liver Transplantation: Case Report and Review of the Literature.Clinical case reports · 2025Article
- Immune checkpoint inhibitors in hepatocellular carcinoma therapy: resistance mechanisms, liver transplantation challenges and management strategies.Cancer drug resistance (Alhambra, Calif.) · 2025Review
- Downstaging with atezolizumab-bevacizumab: a case series.Journal of liver cancer · 2024Article
- Review
- Management of hepatocellular carcinoma recurrence after liver surgery and thermal ablations: state of the art and future perspectives.Hepatobiliary surgery and nutrition · 2024Review
- Hepatocellular Carcinoma: The Role of Immunotherapy and Transplantation in the Era of Transplant Oncology.Cancers · 2023Review
- The evolving role of lenvatinib at the new era of first-line hepatocellular carcinoma treatment.Clinical and molecular hepatology · 2023Review
- Immunotherapy and Liver Transplantation: A Narrative Review of Basic and Clinical Data.Cancers · 2023Review
- Immune checkpoint inhibitors in liver transplant: a case series.Journal of gastrointestinal oncology · 2023Article
- Review
- Immunotherapy for Hepatocellular Carcinoma in the Setting of Liver Transplantation: A Review.International journal of molecular sciences · 2023Review
- Use of immune checkpoint inhibitors in solid organ transplant recipients with advanced cutaneous malignancies.Frontiers in transplantation · 2023Article
- Role of immunotherapy in downsizing hepatocellular carcinoma prior to liver transplantation.World journal of transplantation · 2022Review
- Advances and effectiveness of the immunotherapy after liver transplantation.World journal of gastrointestinal surgery · 2022Article
- Immunotherapy for advanced hepatocellular carcinoma: From clinical trials to real-world data and future advances.World journal of clinical oncology · 2022Review
- Understanding immune perspectives and options for the use of checkpoint immunotherapy in HCC post liver transplant.Hepatoma research · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThere is limited evidence on the safety of immunotherapy use after liver transplantation and its efficacy in treating post-liver transplant hepatocellular carcinoma (HCC) recurrence.
aimTo assess the safety of immunotherapy after liver transplant and its efficacy in treating post-liver transplant HCC recurrence.
methodsA literature review was performed to identify patients with prior liver transplantation and subsequent immunotherapy. We reviewed the rejection rate and risk factors of rejection. In patients treated for HCC, the oncological outcomes were evaluated including objective response rate, progression-free survival (PFS), and overall survival (OS).
resultsWe identified 25 patients from 16 publications and 3 patients from our institutional database (total
conclusionRejection risk is the major obstacle to immunotherapy use in liver transplant recipients. Further studies on the potential risk factors of rejection are warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.